Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14827779 | 0.85 | HTR1D (0.57) | KIF11ATMHTR1DLMNAAURKA | |
| SCHEMBL888682 | 0.81 | KIF11 (0.49) | KIF11HTR1DLMNAAURKADAPK3 | |
| SCHEMBL23479567 | 0.79 | ALDH1A1 (0.48) | KIF11HTR1DLMNAAURKADAPK3 | |
| SCHEMBL7916229 | 0.79 | PRKAB2 (0.48) | KIF11HTR1DLMNAAURKADAPK3 | |
| SCHEMBL12219900 | 0.77 | TBK1 (0.40) | KIF11HTR1DLMNAAURKADAPK3 | |
| SCHEMBL21008475 | 0.77 | HTR1D (0.53) | KIF11HTR1DHTR1BEIF4A3HTR2A | |
| SCHEMBL24819171 | 0.77 | KIF11 (0.45) | KIF11HTR1DLMNAAURKADAPK3 | |
| SCHEMBL14827041 | 0.77 | KIF11 (0.45) | KIF11HTR1DLMNAAURKADAPK3 | |
| SCHEMBL29555842 | 0.75 | ATM (0.56) | KIF11ATMHTR1DLMNAHTR2A | |
| SCHEMBL12352 | 0.75 | ATM (0.56) | KIF11ATMHTR1DLMNAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112830-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-06-16 | — | — | US | disclosed |
| WO-2019243303-A1 | PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2019-12-26 | — | — | WO | disclosed |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2019-11-21 | — | — | US | disclosed |
| US-8221737-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110217261-A1 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KIF11 3339/4885ATM 4843/4885HTR1D 4814/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KIF11 3339/4885ATM 4843/4885HTR1D 4814/4885 |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | KIF11 3600/4885ATM 4826/4885HTR1D 4827/4885 |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KIF11 3339/4885ATM 4843/4885HTR1D 4814/4885 |
| US-20110217261-A1 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION | HAVCR2, EIF2AK2, MAVS | KIF11 3921/4885ATM 3815/4885HTR1D 4579/4885 |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | KIF11 4632/4885ATM 4273/4885HTR1D 1138/4885 |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | KIF11 3016/4885ATM 4874/4885HTR1D 4795/4885 |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | STAT3, JAK2, STAT5A | KIF11 3324/4885ATM 1518/4885HTR1D 3677/4885 |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KIF11 3339/4885ATM 4843/4885HTR1D 4814/4885 |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | KIF11 3600/4885ATM 4826/4885HTR1D 4827/4885 |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | NSUN2, HCCS, HAVCR2 | KIF11 2987/4885ATM 4874/4885HTR1D 4792/4885 |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | HLA-DRB1, CD74, HLA-C | KIF11 3828/4885ATM 1243/4885HTR1D 4169/4885 |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | KIF11 3600/4885ATM 4826/4885HTR1D 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.